MBHB Partner Kevin Noonan shares thoughts on a biotech platform company’s use of alternative strategies to obtain patents for new versions of existing drugs
July 17, 2024
In Bloomberg Law, MBHB Partner Kevin Noonan discusses Terran Biosciences, Inc.’s approach to fast-track drug approval via the 505(b)(2) pathway strategy. View the article.